首页> 美国卫生研究院文献>BMJ Open Access >Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised double-blind placebo-controlled phase 3 trial

【2h】

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised double-blind placebo-controlled phase 3 trial

机译：抗RANKL抗体denosumab对类风湿关节炎患者使用传统的合成疾病缓解性抗风湿药治疗的关节结构损伤的影响（DESIRABLE研究）：一项随机双盲安慰剂对照的3期试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectiveTo evaluate the efficacy of denosumab in suppressing joint destruction when added to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in patients with rheumatoid arthritis (RA).

机译：目的评估地诺单抗在类风湿关节炎（RA）患者中加入常规的综合性疾病改良抗风湿药（csDMARD）治疗后抑制关节破坏的功效。

著录项

期刊名称 BMJ Open Access
作者
Tsutomu Takeuchi; Yoshiya Tanaka; Satoshi Soen; Hisashi Yamanaka; Toshiyuki Yoneda; Sakae Tanaka; Takaya Nitta; Naoki Okubo; Harry K Genant; Désirée van der Heijde;
展开▼
作者单位

展开▼
年(卷),期 -1(78),7
年度 -1
页码 899–907
总页数 9
原文格式 PDF
正文语种
中图分类
关键词
rheumatoid arthritis denosumab joint destruction erosion;

机译：类风湿关节炎;denosumab;关节破坏;糜烂;

相似文献

外文文献
中文文献

1. Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial [J] . Takeuchi Tsutomu, Tanaka Yoshiya, Soen Satoshi, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2019 ,第7期

机译：抗rankl抗体Denosumab对常规综合性疾病修饰抗腹炎治疗类风湿性关节炎患者联合结构损伤的影响（理想的研究）：随机，双盲，安慰剂控制第3期试验
2. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial [J] . Burmester Gerd R., Kremer Joel M., Van den Bosch Filip, The Lancet . 2018 ,第10139期

机译：upadacitinib在类风湿性关节炎患者中的安全性和疗效和对常规合成疾病改性抗风湿药物的反应不足（选择 - 下一步）：随机，双盲，安慰剂控制第3期试验
3. Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: Results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks [J] . TakeuchiT., HarigaiM., TanakaY., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2013 ,第9期

机译：虽然先前治疗疾病改性抗胃癌，但疾病改性抗胃癌的日本患者的Golimalab单一疗法
4. Original article: Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs [O] . Desirée van der Heijde, Maxime Dougados, Ying-Chou Chen, 2018

机译：原始文章：Baricitinib对类风湿关节炎患者1年结构性关节损伤的影像学进展的影响以及对传统的合成疾病缓解类风湿药的反应不足
5. Effects of an Anti-RANKL Antibody Denosumab on Joint Structural Damage in Patients with Rheumatoid Arthritis Treated with Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (DESIRABLE Study): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial [O] . Tsutomu Takeuchi, Yoshiya Tanaka, Satoshi Soen, 2018

机译：抗RANKL抗体Denosumab对用常规合成疾病改性抗风湿药物治疗类风湿性关节炎患者联合结构损伤的影响（理想的研究）：随机，双盲，安慰剂控制第3期试验

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised double-blind placebo-controlled phase 3 trial

摘要

著录项

相似文献

相关主题

期刊订阅